The board of directors of the pharmaceutical company Double Bond Pharmaceutical has resolved on a directed set-off share issue of B shares to Investentia. The issue amounts to approximately SEK 1 million and settles part of a loan agreement of up to SEK 5 million.The subscription price is SEK 0.117 per share, corresponding to 80 percent of the volume-weighted average price over 90 trading days on Spotlight."This set-off share issue is a planned step to further strengthen the Company's financial flexibility. With a stronger financial position, our prospects are significantly improved in upcoming negotiations on commercial agreements for our key project SI053. We see this as an important step to maximize and create the greatest possible shareholder value in the long term", says Igor Lokot, CEO of Double Bond Pharma.